A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostatic Cancer, Castration-Resistant
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 138 (final count)
- Started
- Jul 3, 2025
- Main results expected
- Jul 16, 2027
- Fully finished
- May 14, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Prostate Specific Antigen 50 (PSA50) Rate
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
Incidence rate of adverse events (AEs)
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
Number of participants with dose adjustments
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
Duration of exposure to study treatment
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07047118 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC